Friday, July 10, 2026

pharma · Not applicable, Healthy Volunteers · advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

mAbxience

Mabxience Research SL is a pharma organization headquartered in Madrid, ES. Primary therapeutic focus areas include Not applicable, Healthy Volunteers, advanced/metastatic non-squamous non-small cell lung cancer (NSCLC),

madrid, ES HQ
2009 Founded
1,194 Employees
EMA registrant Type
Company details
Status
Public
HQ
madrid, ES
Founded
2009
Employees
1,194
Programs
5
Drugs
10
Patents
0
Clinical program

MB12-C-02-24

Phase 3 · other · advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

MB12-C-02-24 for advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) is a Phase 3 program (other) at Mabxience Research SL with 1 ClinicalTrials.gov record(s).

Internal code MB12-C-02-24

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Mabxience Research SL
Phase
Phase 3
Modality
other
Indication
advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
Status
active
Trials
1